Drug Overview

Thioureidobutyronitrile, also known by its investigational name Kevetrin, is a specialized “smart drug” being studied for its ability to fight cancer. It is not a traditional chemotherapy that attacks all fast-growing cells. Instead, it is a small molecule p53 activator. This means it works by turning on a natural “security guard” protein in your body that tells cancer cells to stop growing or to destroy themselves.

The drug is currently being tested in advanced clinical trials. This means it is an investigational drug and is not yet available for the general public at a local pharmacy. Doctors and scientists are looking at how it can help patients whose cancer has stopped responding to other treatments.

Key Details

• Generic Name: Thioureidobutyronitrile (pronounced: thigh-oh-yur-ee-doh-byoo-ty-roh-ny-tril).
• US Brand Names: None yet. It is often called Kevetrin in clinical research.
• Drug Class: p53 Activator / Small Molecule Antineoplastic Agent.
• Route of Administration: Intravenous (IV) injection or infusion into the bloodstream.
• FDA Approval Status: Investigational. It is currently being studied in clinical trials and has not received full FDA approval for standard use.

What Is It and How Does It Work? (Mechanism of Action)

To understand how thioureidobutyronitrile works, it helps to think of your cells as having a master “security guard.” This guard is a protein called p53. Its job is to watch for damage in the cell’s DNA. If the DNA is damaged, p53 stops the cell from dividing until it is fixed. If the damage is too bad to fix, p53 tells the cell to “self-destruct” so it doesn’t turn into a tumor.

Because of this, p53 is often called the “Guardian of the Genome.”

In about half of all human cancers, this security guard is “broken” or missing. This happens because of a mutation (a mistake) in the gene that makes the p53 protein. Without a working p53, cancer cells can grow and spread without anything to stop them. Thioureidobutyronitrile is designed to fix this problem at the molecular level.

The Step-by-Step Process

1. Entering the Cell: After the drug is given through an IV, it travels through the blood and enters the cancer cells.
2. Waking Up the Guard: Once inside, the drug finds the p53 protein. Even if the protein is mutated or being held “hostage” by other proteins (like one called MDM2), the drug helps “wake it up.” It does this by adding a chemical tag (called phosphorylation) to a specific part of the p53 protein.
3. Breaking the Chains: This chemical tag makes it hard for the “bad” proteins like MDM2 to keep p53 inactive. The p53 protein becomes stable and can finally do its job again.
4. Stopping the Cancer: The active p53 then turns on other “helper” proteins, such as p21 and PUMA.
   • p21 acts like a “brake,” stopping the cell from dividing.
   • PUMA acts like a “switch,” triggering apoptosis (programmed cell death).
5. Targeting Resistance: Because it works on the p53 pathway, thioureidobutyronitrile may be able to kill cancer cells that have become “immune” or resistant to standard chemotherapy.

FDA-Approved Clinical Indications

Currently, thioureidobutyronitrile does not have official FDA-approved indications for routine medical use. It is only available to patients who are enrolled in approved clinical trials.

Researchers are studying it for the following uses:

Oncological Uses (In Clinical Trials):

• Advanced Solid Tumors: This includes cancers of the lungs, colon, and breast that have spread to other parts of the body.
• Ovarian Cancer: Especially cases where the cancer has returned after previous treatments.
• Drug-Resistant Cancers: Used for patients whose tumors have a mutated p53 gene and no longer respond to normal chemo.
• Leukemia and Lymphoma: It is being studied to see if it can help restart the immune response in blood-related cancers.

Non-oncological Uses:

• While primarily a cancer drug, early research is looking at how p53 activation might help in regenerative medicine and protecting healthy tissues from radiation damage.

Dosage and Administration Protocols

Thioureidobutyronitrile is given by medical professionals in a hospital or clinic setting. It is usually given in “cycles,” which means you receive the drug for a few days and then have a rest period to let your body recover.

Clinical Efficacy and Research Results

Recent clinical data from studies conducted between 2020 and 2025 have provided promising information about how this drug helps patients. Because it is in the early stages (Phase 1 and Phase 2), the main goal has been to find the safest dose, but many patients have shown positive responses.

• Tumor Stabilization: In trials involving patients with very advanced “solid tumors,” researchers found that a significant number of patients reached “stable disease.” This means their tumors stopped growing for several months.
• Reduction in Symptoms: In some cases, patients reported feeling more energy. Doctors also observed a reduction in ascites (fluid buildup in the belly), which is a common and painful problem in late-stage ovarian and liver cancers.
• Biomarker Success: Blood tests in these trials showed that the drug successfully increased the levels of p21 in the body. This proves the drug is “hitting its target” and waking up the p53 protein as intended.
• Overcoming Resistance: Early results suggest that patients with “mutant p53”, the hardest type of cancer to treat, may still respond to thioureidobutyronitrile.

Safety Profile and Side Effects

One of the most exciting things about thioureidobutyronitrile is its safety profile. Unlike standard chemotherapy, which often causes hair loss and severe sickness, this drug has been well-tolerated in most patients.

Common Side Effects (>10%)

• Fatigue: A general feeling of being tired or having low energy.
• Nausea: Mild stomach upset, usually manageable with standard anti-nausea medicine.
• Headache: Some patients report mild to moderate headaches shortly after the infusion.
• Infusion Site Reaction: Redness or a cool feeling in the arm where the IV is placed.

Serious Adverse Events (Rare)

• Low Blood Counts: While less common than with standard chemo, a drop in white blood cells (neutropenia) can occur.
• Allergic Reaction: As with any medicine given by IV, there is a small risk of a “hypersensitivity” reaction (hives, trouble breathing).

Management Strategies

• For Fatigue: Patients are encouraged to rest and stay hydrated.
• For Nausea: Doctors often give “pre-meds” (medicine before the treatment) to prevent stomach upset.
• Monitoring: Regular blood tests are performed to check the liver, kidneys, and blood cell counts.

Research Areas: Stem Cells and Immunotherapy

Scientists are currently looking at how thioureidobutyronitrile can be used in combination therapies.

One area of interest is immunotherapy. Because p53 helps the immune system recognize “stressed” cells, using this drug might make cancer cells more visible to the body’s natural defenses. There is also research into using p53 activators to protect hematopoietic stem cells (the cells that make your blood) from the toxic effects of radiation, which could make cancer treatments safer in the future.

Patient Management and Practical Recommendations

If you are participating in a clinical trial for this drug, your medical team will give you specific instructions.

Pre-treatment Tests

• Genetic Testing: A biopsy or blood test is often done to see if your tumor has a p53 mutation.
• Blood Panels: Full tests of your liver and kidney function are required before every cycle.
• Imaging: A baseline CT or MRI scan is done to measure the size of the tumor.

“Do’s and Don’ts” List

• DO drink plenty of water (8-10 glasses) the day before your treatment.
• DO tell your doctor about all other medicines you take, including vitamins.
• DON’T skip your blood test appointments, as these are vital for your safety.
• DON’T drive yourself home after your first infusion until you know how the drug affects you.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Thioureidobutyronitrile (Kevetrin) is an investigational drug and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.